1. Home
  2. PENG vs SGP Comparison

PENG vs SGP Comparison

Compare PENG & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Penguin Solutions Inc. Ordinary Shares

PENG

Penguin Solutions Inc. Ordinary Shares

HOLD

Current Price

$44.70

Market Cap

959.2M

Sector

Technology

ML Signal

HOLD

SGP

SpyGlass Pharma Inc. Common Stock

N/A

Current Price

$24.00

Market Cap

932.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PENG
SGP
Founded
1988
2019
Country
United States
United States
Employees
2900
N/A
Industry
Semiconductors
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
959.2M
932.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PENG
SGP
Price
$44.70
$24.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
5
Target Price
$27.78
$45.00
AVG Volume (30 Days)
2.2M
55.7K
Earning Date
04-01-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.55
N/A
Revenue Next Year
$16.14
N/A
P/E Ratio
$87.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.04
$20.15
52 Week High
$46.75
$30.56

Technical Indicators

Market Signals
Indicator
PENG
SGP
Relative Strength Index (RSI) 87.36 50.07
Support Level $22.13 $20.95
Resistance Level N/A $26.55
Average True Range (ATR) 2.90 1.49
MACD 1.31 0.11
Stochastic Oscillator 88.41 62.24

Price Performance

Historical Comparison
PENG
SGP

About PENG Penguin Solutions Inc. Ordinary Shares

Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.

About SGP SpyGlass Pharma Inc. Common Stock

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Share on Social Networks: